Leading the Future of Precision Immunotherapy

Alithea Bio: Pioneering HLA peptide Characterization with Innovative Immunopeptidomics, highly sensitive Mass Spectrometry and applied AI

Unified bioinformatics pipeline
Stringent 
quality control
Mapping all peptides to cognate HLA alleles
Relative quantification between thousands of samples
Tools to identify off-targets
Intuitive user interface

HLA-Compass

Navigate the Immunopeptidome with Confidence

HLA-Compass is the world’s largest immunopeptidomics database, designed to guide drug developers through the complexity of immune-target interactions. By combining high-throughput mass spectrometry with curated healthy and tumor tissue data, HLA-Compass helps you identify true targets, assess off-target toxicity, and de-risk your immunotherapy pipeline — all in one powerful platform.

Our Commitment

We are world leaders in HLA peptide quantification, enhancing the precision and effectiveness of therapeutic solutions to ensure safer and more effective options for patients. Alithea Bio is at the forefront of revolutionizing cancer treatment through groundbreaking T-cell therapies.

Our Goal

We aim for a future where innovative TCR therapies and a comprehensive HLA peptide database enable more effective and safer cancer treatments.

Alithea Bio combines cutting-edge immunopeptidomics methods, highly sensitive mass spectrometry, and AI to provide world-leading results in the characterization of HLA peptides from cell lines, tissues, and blood.

Products

Our product suite empowers immunotherapy developers with end-to-end solutions — from raw patient tissue to clinical insight. Whether you’re searching for novel antigens, validating TCR specificity, or ensuring safety through off-target prediction, Alithea Bio delivers the tools to move faster, with greater precision.

Explore our SaaS platform, mass spectrometry services, and AI-powered analytics.

HLA- Compass

Our web-accessible HLA peptide database HLA Compass comprises 1.4 million unique peptides and 10,000 cancer specific epitopes deriving from >17 million identifications in 4,160 high-quality HLA peptidomics samples, meticulously collected from healthy organs, cancer cell lines, and tumor tissues.

Learn more

HLA Peptide Binding Predictions

Predict which peptides will bind to specific HLA molecules — fast and reliably. Our AI-powered tools combine biological relevance and computational precision to support epitope discovery, vaccine design, and immunotherapy development.

Learn more

NeoZOOM

A cutting-edge mass spectrometry service for ultra-sensitive profiling of HLA peptides directly from tumor or tissue samples. NeoZOOM helps you zoom in on the targets that matter most — with unmatched depth and accuracy.

Learn more

Off-Target Toxicity Prediction

Reduce risk before it reaches the clinic. Our platform integrates proprietary healthy tissue data and machine learning models to predict potential off-target peptide binding — helping you design safer TCR, TCRm, and antibody therapies.

Learn more

Kits

Standardized kits for sample preparation and peptide enrichment, tailored for HLA immunopeptidomics workflows. Designed to ensure reproducibility, scalability, and compatibility with mass spectrometry and downstream analytics.

Learn more

Technology

Our proprietary technology combines high-sensitivity mass spectrometry with advanced bioinformatics and machine learning to reveal the full complexity of HLA-presented peptides — enabling safer, more effective drug development. From tumor profiling to target validation and toxicity prediction, we turn deep biology into actionable insight.

Explore our core technology pillars.

Stay updated

    Subscribe to our Newsletter